Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
NCT00364780
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small-cell Lung Cancer
Interventions
DRUG:
XL647
Sponsor
Kadmon Corporation, LLC